세계의 멀티오믹스 서비스 시장 규모, 점유율, 동향 분석 : 서비스별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Multiomics Services Market Growth & Trends:

The global multiomics services market size is projected to reach USD 4.72 billion by 2033, growing at a CAGR of 17.41% from 2025 to 2033, according to a new report by Grand View Research, Inc. The multiomics services industry is witnessing accelerated growth, driven by the increasing demand for integrated biological data to enable precision medicine, advanced diagnostics, and systems biology research. As the need to understand complex biological mechanisms intensifies, multiomics approaches combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics are becoming essential tools for comprehensive biomarker discovery, disease stratification, and therapeutic development.

Pharmaceutical and biotechnology companies, research institutions, and clinical laboratories increasingly leverage multiomics platforms to gain deeper insights into disease pathways, therapeutic targets, and patient-specific responses. Strategic collaborations, rising R&D investments, and technological convergence catalyze innovation in multiomics service offerings while enhancing data integration and interpretability across diverse omics layers.

The growing adoption of multiomics in oncology, immunology, neurology, and infectious disease research further fueled the market's expansion. As regulatory frameworks around data quality, privacy, and clinical validation tighten, service providers invest in robust quality control systems, secure data management solutions, and AI-driven analytics to meet evolving customer and compliance needs. Multiomics services are reshaping the future of translational medicine and individualized healthcare by offering holistic views of biological systems and disease progression.

With the rapid evolution of omics technologies and the growing demand for precision insights, the multiomics services market is positioned to become a cornerstone of next-generation biomedical innovation and global health transformation.

Multiomics Services Market Report Highlights:

• The research services segment accounted for the largest market revenue share in 2024. This leadership derives from their foundational role in supporting preclinical studies, mechanistic research, and early-stage drug discovery. As multiomics approaches become integral to understanding complex disease biology, academic and commercial research demand continues to rise.
• The bulk multiomics segment accounted for the largest market revenue share in 2024, owing to its widespread adoption in large-scale studies and established workflows in genomics, transcriptomics, and proteomics. These approaches are widely used in population-level biomarker discovery, disease profiling, and target validation. Advances in single cell sequencing technologies continue to drive adoption across oncology, immunology, and neuroscience research.
• The drug discovery & development segment led the market with the largest revenue share of 35.45% in 2024, driven by the growing need for integrated data to accelerate target identification and streamline R&D. However, the synthetic biology segment is expected to grow at the fastest CAGR of 19.40% over the forecast period.
• The pharmaceutical and biotechnology segment accounted for the largest market revenue share in 2024. These organizations integrate multiomics into R&D workflows to accelerate precision drug development, companion diagnostics, and therapeutic optimization. Increasing collaborations with contract research organizations (CROs) and multiomics platform providers support this segment.
• North America dominated the market with the largest revenue share of 40.13% in 2024. This is attributed to advanced healthcare infrastructure, strong genomics research funding, and early adoption of omics technologies. However, Asia Pacific is expected to grow at the highest CAGR of 19.62% over the forecast period.
• In January 2025, NVIDIA announced strategic partnerships with IQVIA, Illumina, Mayo Clinic, and Arc Institute to revolutionize genomics, drug discovery, and healthcare. The initiatives focus on developing AI agents to expedite clinical trials, AI models for drug discovery and digital pathology, and physical AI robots for surgery and patient monitoring.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Service Segment
  • 1.2.2. Type Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Multiomics Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Multiomics Services Market: Service Business Analysis

• 4.1. Service Segment Dashboard
• 4.2. Global Multiomics Services Market Service Movement Analysis
• 4.3. Global Multiomics Services Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Research Services
  • 4.4.1. Global Research Services based Market, 2021 - 2033 (USD Million)
• 4.5. Data Analysis Services
  • 4.5.1. Global Data Analysis Services Market, 2021 - 2033 (USD Million)

Chapter 5. Multiomics Services Market: Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. Global Multiomics Services Market Type Movement Analysis
• 5.3. Global Multiomics Services Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Single-cell Multiomics
  • 5.4.1. Global Single-cell Multiomics Market, 2021 - 2033 (USD Million)
• 5.5. Bulk Multiomics
  • 5.5.1. Global Bulk Multiomics Market, 2021 - 2033 (USD Million)

Chapter 6. Multiomics Services Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Multiomics Services Market Application Movement Analysis
• 6.3. Global Multiomics Services Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Biomarker Discovery Market
  • 6.4.1. Global Biomarker Discovery Market, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. Global Drug Discovery & Development Market, 2021 - 2033 (USD Million)
• 6.6. Synthetic Biology
  • 6.6.1. Global Synthetic Biology Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Global Others Market, 2021 - 2033 (USD Million)

Chapter 7. Multiomics Services Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Multiomics Services Market End Use Movement Analysis
• 7.3. Global Multiomics Services Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Global Pharmaceutical and Biotechnology Companies Devices Market, 2021 - 2033 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Global Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Global Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Multiomics Services Market: Region Estimates & Trend Analysis

• 8.1. North America
  • 8.1.1. North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.1.2. U.S.
    • 8.1.2.1. Key country dynamics
    • 8.1.2.2. Competitive scenario
    • 8.1.2.3. Regulatory Framework
    • 8.1.2.4. Target Disease Prevalence
    • 8.1.2.5. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.1.3. Canada
    • 8.1.3.1. Key country dynamics
    • 8.1.3.2. Competitive scenario
    • 8.1.3.3. Regulatory Framework
    • 8.1.3.4. Target Disease Prevalence
    • 8.1.3.5. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.1.4. Mexico
    • 8.1.4.1. Key country dynamics
    • 8.1.4.2. Competitive scenario
    • 8.1.4.3. Regulatory Framework
    • 8.1.4.4. Target Disease Prevalence
    • 8.1.4.5. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.2. Europe
  • 8.2.1. Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.2. UK
    • 8.2.2.1. Key country dynamics
    • 8.2.2.2. Competitive scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.3. Germany
    • 8.2.3.1. Key country dynamics
    • 8.2.3.2. Competitive scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.4. France
    • 8.2.4.1. Key country dynamics
    • 8.2.4.2. Competitive scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.5. Italy
    • 8.2.5.1. Key country dynamics
    • 8.2.5.2. Competitive scenario
    • 8.2.5.3. Regulatory Framework
    • 8.2.5.4. Target Disease Prevalence
    • 8.2.5.5. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.6. Spain
    • 8.2.6.1. Key country dynamics
    • 8.2.6.2. Competitive scenario
    • 8.2.6.3. Regulatory Framework
    • 8.2.6.4. Target Disease Prevalence
    • 8.2.6.5. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.7. Norway
    • 8.2.7.1. Key country dynamics
    • 8.2.7.2. Competitive scenario
    • 8.2.7.3. Regulatory Framework
    • 8.2.7.4. Target Disease Prevalence
    • 8.2.7.5. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.8. Sweden
    • 8.2.8.1. Key country dynamics
    • 8.2.8.2. Competitive scenario
    • 8.2.8.3. Regulatory Framework
    • 8.2.8.4. Target Disease Prevalence
    • 8.2.8.5. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.2.9. Denmark
    • 8.2.9.1. Key country dynamics
    • 8.2.9.2. Competitive scenario
    • 8.2.9.3. Regulatory Framework
    • 8.2.9.4. Target Disease Prevalence
    • 8.2.9.5. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.3. Asia Pacific
  • 8.3.1. Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Japan
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Competitive scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. China
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Competitive scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. India
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Competitive scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.5. Thailand
    • 8.3.5.1. Key country dynamics
    • 8.3.5.2. Competitive scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.6. South Korea
    • 8.3.6.1. Key country dynamics
    • 8.3.6.2. Competitive scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.7. Australia
    • 8.3.7.1. Key country dynamics
    • 8.3.7.2. Competitive scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.4. Latin America
  • 8.4.1. Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Brazil
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Argentina
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Middle East & Africa
  • 8.5.1. Middle East & Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. South Africa
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Saudi Arabia
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. UAE
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Kuwait
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Bio-Techne
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. CD Genomics
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. RayBiotech, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. . Creative Proteomics
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Psomagen
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Source BioScience
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Persistent Systems
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Metware Biotechnology Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Dalton Bioanalytics Inc.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Sapient Bioanalytics, LLC.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives